{"title": "Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial", "doi": "10.1101/2020.03.17.20037432", "citation_id": "2020.03.17.20037432v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.17.20037432", "abstract": "<p>Importance: WHO has made the assessment that coronavirus disease 2019 (COVID-19) can be characterized as a pandemic. But there is no effective antiviral drug for COVID-19 so far.\nObjective: To compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients on 7 day\u2032s clinical recovery rate.\nDesign: Prospective, multicenter, open-label, randomized superiority trial in February, 2020.\nSetting: Multicenter study.\nParticipants: Patients with confirmed COVID-19 admitted to 3 hospitals from Feb 20, 2020 to Mar 12, 2020.\nInterventions: Conventional therapy + favipiravir or arbidol.\nMain Outcomes and Measures: \nThe primary outcome was 7 day\u2032s clinical recovery rate. Duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate were the secondary outcomes. The patients with chest CT imaging and laboratory-confirmed COVID-19 infection, aged 18 years or older were randomly assigned to receive favipiravir or arbidol. Safety data were collected for a further 1 weeks\u2032 follow-up. \nResults: 120 patients were assigned to favipiravir group (116 assessed) and 120 to arbidol group (120 assessed). In FAS cohort, for ordinary patients with COVID-19, 7 day\u2032s clinical recovery rate was 55.86% in the arbidol group and 71.43% in the favipiravir group (P = 0.0199). For ordinary COVID-19 patients and COVID-19 patients with hypertension and/or diabetes, the time of fever reduction and cough relief in favipiravir group was significantly shorter than that in arbidol group (both P &lt; 0.001), but there was no statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate (both P &gt; 0.05). The most possible adverse events were abnormal LFT, psychiatric symptom reactions, digestive tract reactions and raised serum uric acid (3 [2.50 %] in arbidol group vs 16 [13.79%] in favipiravir group, P &lt; 0.0001).\nConclusions and Relevance: In ordinary COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment because of its\u2032 higher 7 day\u2032s clinical recovery rate and more effectively reduced incidence of fever, cough except some antiviral-associated adverse effects.\nTrial Registration: This study is registered with Chictr.org.cn, number ChiCTR200030254.</p>", "twitter_description": "Importance: WHO has made the assessment that coronavirus disease 2019 (COVID-19) can be characterized as a pandemic. But there is no effective antiviral drug for COVID-19 so far. Objective: To compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients on 7 day\u2032s clinical recovery rate. Design: Prospective, multicenter, open-label, randomized superiority trial in February, 2020. Setting: Multicenter study. Participants: Patients with confirmed COVID-19 admitted to 3 hospitals from Feb 20, 2020 to Mar 12, 2020. Interventions: Conventional therapy + favipiravir or arbidol. Main Outcomes and Measures: The primary outcome was 7 day\u2032s clinical recovery rate. Duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate were the secondary outcomes. The patients with chest CT imaging and laboratory-confirmed COVID-19 infection, aged 18 years or older were randomly assigned to receive favipiravir or arbidol. Safety data were collected for a further 1 weeks\u2032 follow-up. Results: 120 patients were assigned to favipiravir group (116 assessed) and 120 to arbidol group (120 assessed). In FAS cohort, for ordinary patients with COVID-19, 7 day\u2032s clinical recovery rate was 55.86% in the arbidol group and 71.43% in the favipiravir group (P = 0.0199). For ordinary COVID-19 patients and COVID-19 patients with hypertension and/or diabetes, the time of fever reduction and cough relief in favipiravir group was significantly shorter than that in arbidol group (both P < 0.001), but there was no statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate (both P > 0.05). The most possible adverse events were abnormal LFT, psychiatric symptom reactions, digestive tract reactions and raised serum uric acid (3 [2.50 %] in arbidol group vs 16 [13.79%] in favipiravir group, P < 0.0001). Conclusions and Relevance: In ordinary COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment because of its\u2032 higher 7 day\u2032s clinical recovery rate and more effectively reduced incidence of fever, cough except some antiviral-associated adverse effects. Trial Registration: This study is registered with Chictr.org.cn, number ChiCTR200030254.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nChiCTR200030254\n\n### Funding Statement\n\nThis work was supported by the National Key Research and Development Program of China (2020YFC0844400).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nWith the permission of the corresponding author, we can provide participant data, statistical analysis.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.17.20037432v1", "access_rights": "restricted", "authors": ["Chang Chen", "Jianying Huang", "Zhenshun Cheng", "Jianyuan Wu", "Song Chen", "Yongxi Zhang", "Bo Chen", "Mengxin Lu", "Yongwen Luo", "Jingyi Zhang", "Ping Yin", "Xinghuan Wang"]}